Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01838499 · ClinicalTrials.gov registry record · Phase 2
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT01838499 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 224 participants.
The verdict
NCT01838499, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL MEDI8968
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01838499
The ClinicalTrials.gov registry entry for NCT01838499 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT01838499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01838499 about?
NCT01838499 is a clinical study titled "Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa". The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa
What is the current status of trial NCT01838499?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2013-05. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01838499?
The interventions under investigation include: Saline (BIOLOGICAL), MEDI8968 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01838499?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.